Reviva Pharmaceuticals Holdings, Inc. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $431.97 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-03-30
- Reviva Pharmaceuticals Holdings, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $431.97K, a 43.76% decline from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $768.06K, a 19.89% increase from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $640.64K.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $431.97K 10-K · filed 2026-03-30 |
| 2024-12-31 | $768.06K 10-K · filed 2026-03-30 |
| 2023-12-31 | $640.64K 10-K · filed 2025-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |